{"title":"Moderna’s data in kids ages 12-17 “consistent with a vaccine efficacy of 100%”","link":"https://arstechnica.com/?p=1767658","date":1621981734000,"content":"<div>\n<figure><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2021/03/GettyImages-1309098061-800x533.jpeg\" /><p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2021/03/GettyImages-1309098061.jpeg\">Enlarge</a> <span>/</span> A vial of the current Moderna COVID-19 vaccine. (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/detail-of-a-dose-of-the-moderna-covid-19-vaccine-shown-by-a-news-photo/1309098061?adppopup=true\">Getty | Ivan Romano</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>Moderna’s COVID-19 vaccine appears safe and highly effective in adolescents ages 12 to 17, according to the top-line results of a small clinical trial the company announced Tuesday.</p>\n<p>The company plans to submit the trial data to the US Food and Drug Administration early next month, seeking authorization for expanded use in the age group.</p>\n<p>If the FDA grants the authorization, Moderna’s vaccine will be the second COVID-19 vaccine available for use in kids as young as 12 in the US. Earlier this month, the FDA authorized the Pfizer-BioNTech vaccine for use in adolescents ages 12 to 15. (The Pfizer-BioNTech vaccine was initially authorized for use in people ages 16 and up, while Moderna’s was initially authorized for use in people ages 18 and up.)</p></div><p><a href=\"https://arstechnica.com/?p=1767658#p3\">Read 5 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1767658&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"49a374c8758f9ac6e602a5612653a5c3eaa3f0bf19eb7ff22d25a07d8d201e5c","category":"Tech"}